Gossamer Bio, Inc. (GOSS)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
9.76 USD
+0.48
(5.172%)
⇧
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 9.45 -0.31 (-0.310%) ⇩ (Oct. 13, 2026, 6:18 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 4:28 a.m. EDT
The investment case for Gossamer Bio is currently paralyzed by a severe liquidity and solvency crisis, rendering both short-term momentum and long-term fundamentals ineffective. While the company possesses a promising drug candidate highlighted by recent FDA updates, the financial reality is dire: negative free cash flow of nearly $30 million, negative operating cash flow exceeding $160 million, and a current ratio of just 0.53. The balance sheet is fragile, with debt significantly outweighing cash reserves, creating an imminent covenant risk that looms over any potential clinical success. The market has priced this correctly, evidenced by the crushing 94% drop from the 52-week high and the overwhelming put-heavy options flow which signals fear rather than hope. With no dividend to provide income and a business burning through capital without a proven commercialized product, the risk-reward profile remains deeply skewed toward total loss until the funding gap is bridged. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.134602 |
| MSTL | 0.165162 |
| AutoETS | 0.166490 |
| AutoTheta | 0.166827 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 5.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.345 |
| Excess Kurtosis | -0.97 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 16.806 |
| Market Cap | 59,695,976 |
| Forward P/E | -0.63 |
| Beta | 2.21 |
| Profit Margins | -235.00% |
| Website | https://www.gossamerbio.com |
As of Oct. 10, 2026, 4:28 a.m. EDT: Options activity reveals a distinct lack of bullish positioning. Call volume is negligible across all expirations, with open interest concentrated entirely in deep out-of-the-money strikes (below $3), suggesting speculative lottery tickets rather than directional bets. Conversely, put open interest is significant relative to call volume, particularly in the $1-$3 range for near-term expirations and the $7 strike for longer-dated contracts. This heavy put skew indicates that market participants are hedging against downside risk or betting on further declines, despite the recent news of FDA progress.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9512605 |
| Address1 | 3,115 Merryfield Row |
| Address2 | Suite 120 |
| All Time High | 2,172.0 |
| All Time Low | 8.99 |
| Ask | 10.3 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 286,250 |
| Average Daily Volume3 Month | 376,785 |
| Average Volume | 376,785 |
| Average Volume10Days | 286,250 |
| Beta | 2.206 |
| Bid | 10.4 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | -0.192 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.76 |
| Current Ratio | 0.528 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 10.0343 |
| Day Low | 9.26 |
| Display Name | Gossamer Bio |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,779,105,600 |
| Earnings Call Timestamp Start | 1,779,105,600 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -158,596,992 |
| Ebitda Margins | -2.97634 |
| Enterprise To Ebitda | -0.269 |
| Enterprise To Revenue | 0.801 |
| Enterprise Value | 42,681,300 |
| Eps Current Year | -18.01 |
| Eps Forward | -15.612 |
| Eps Trailing Twelve Months | -52.8 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.3428 |
| Fifty Day Average Change | -2.5828 |
| Fifty Day Average Change Percent | -0.20925559 |
| Fifty Two Week Change Percent | -95.12605 |
| Fifty Two Week High | 309.6 |
| Fifty Two Week High Change | -299.84 |
| Fifty Two Week High Change Percent | -0.9684754 |
| Fifty Two Week Low | 8.99 |
| Fifty Two Week Low Change | 0.77000046 |
| Fifty Two Week Low Change Percent | 0.08565078 |
| Fifty Two Week Range | 8.99 - 309.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,549,636,200,000 |
| Float Shares | 3,824,065 |
| Forward Eps | -15.612 |
| Forward P E | -0.62516016 |
| Free Cashflow | -29,764,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 161 |
| Fullday Change | 0.17000008 |
| Fullday Change Percent | 1.8318974 |
| Fullday Price | 9.45 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 53,286,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01434 |
| Held Percent Institutions | 0.85823995 |
| Implied Shares Outstanding | 6,116,391 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,789,084,800 |
| Last Split Factor | 1:80 |
| Long Business Summary | Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California. |
| Long Name | Gossamer Bio, Inc. |
| Market | us_market |
| Market Cap | 59,695,976 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_548541911 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -125,223,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 66,943,899 |
| Number Of Analyst Opinions | 5 |
| Open | 9.58 |
| Operating Cashflow | -162,626,000 |
| Operating Margins | -2.8224702 |
| Overall Risk | 7 |
| Phone | 858 684 1300 |
| Post Market Change | -0.31000042 |
| Post Market Change Percent | -3.1762338 |
| Post Market Price | 9.45 |
| Post Market Time | 1,791,929,937 |
| Previous Close | 9.28 |
| Price Eps Current Year | -0.54192114 |
| Price Hint | 2 |
| Price To Book | -50.833336 |
| Price To Sales Trailing12 Months | 1.1202939 |
| Profit Margins | -2.35002 |
| Quick Ratio | 0.458 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.4800005 |
| Regular Market Change Percent | 5.172419 |
| Regular Market Day High | 10.0343 |
| Regular Market Day Low | 9.26 |
| Regular Market Day Range | 9.26 - 10.0343 |
| Regular Market Open | 9.58 |
| Regular Market Previous Close | 9.28 |
| Regular Market Price | 9.76 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 477,448 |
| Return On Assets | -0.62391 |
| Revenue Growth | -0.196 |
| Revenue Per Share | 16.806 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 6,116,391 |
| Shares Percent Shares Out | 0.2024 |
| Shares Short | 1,237,721 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,032,916 |
| Short Name | Gossamer Bio, Inc. |
| Short Percent Of Float | 0.2053 |
| Short Ratio | 4.57 |
| Source Interval | 15 |
| State | CA |
| Symbol | GOSS |
| Target High Price | 120.0 |
| Target Low Price | 22.4 |
| Target Mean Price | 82.48 |
| Target Median Price | 90.0 |
| Total Cash | 57,026,000 |
| Total Cash Per Share | 9.332 |
| Total Debt | 40,068,000 |
| Total Revenue | 53,286,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -52.8 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 56.2741 |
| Two Hundred Day Average Change | -46.5141 |
| Two Hundred Day Average Change Percent | -0.8265632 |
| Type Disp | Equity |
| Volume | 477,448 |
| Website | https://www.gossamerbio.com |
| Zip | 92,121 |